The biologics drug substance manufacturing market is witnessing substantial expansion, largely due to the growing prevalence of chronic diseases, which is driving the need for biologics development ...

Peter Bains, Group CEO of Biocon, discusses his outlook and strategy for business growth after the company's latest earnings, ...

Peter Bains, Group CEO of Biocon, talks about India's budget, and the impact of its plans to cut or remove duties on ...

FM’s intent to give relief to patients will be realised more with GST exemption and will make a huge impact, considering that in India 80% of healthcare expenses are out of pocket, writes Biocon ...

Hyderabad: Biopharma major Biocon plans to introduce five new biosimilars in the United States in the new fiscal year, ...

Biocon Biologics CEO discusses revenue growth, market diversification, debt strategy, and impact of US pro-localisation policy.

Biocon plans to list its biosimilars business by March 2026 and aims for a double-digit market share in the U.S. for five new biosimilars launching next fiscal year. The U.S. market, already ...

Tambe said the company, a subsidiary of the Bengaluru-based Biocon Ltd, has five products in the pipeline for launch in the ...

There is market share gain compared to last year. Any biosimilar might be able to take on a four-five or six player market, ...

The company, which has been pushing its IPO plans for the past year, has been waiting to complete the integration of its acquired biosimilars firm Viatris and refinance debt before it goes public ...

Here’s a quick look at stocks likely to be in focus in today's trade. Bank of Baroda: Bank of Baroda posted a 5.6 percent ...